153 related articles for article (PubMed ID: 37226096)
21. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
22. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
23. Concurrent anti-neutrophil cytoplasmic antibody-associated glomerulonephritis and IgG4-associated tubulointerstitial nephritis with C3 glomerulonephritis: A case report.
Feng J; Yu J; Wang X; Wang Y; Liu Y; Xu Z; Sun W
Medicine (Baltimore); 2020 Jan; 99(5):e18857. PubMed ID: 32000387
[TBL] [Abstract][Full Text] [Related]
24. A Case of Switch from C3 Glomerulonephritis to Proliferative Glomerulonephritis with Monoclonal IgG Deposits.
Zhang F; Gao E; Liang S; Yang N; Wang J
Ann Clin Lab Sci; 2018 Jul; 48(4):528-533. PubMed ID: 30143498
[TBL] [Abstract][Full Text] [Related]
25. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
26. De novo C3 glomerulonephritis in a renal allograft.
Nahm JH; Song SH; Kim YS; Cheong HI; Lim BJ; Kim BS; Jeong HJ
Ultrastruct Pathol; 2016; 40(2):112-5. PubMed ID: 26986539
[TBL] [Abstract][Full Text] [Related]
27. [A case of severe colitis induced by the administration of pembrolizumab for pulmonary adenocarcinoma in a patient with ulcerative colitis].
Nishimoto N; Sakakibara Y; Ishida H; Ishihara A; Tanaka S; Hasegawa H; Yamamoto S; Nakazuru S; Mori K; Mita E
Nihon Shokakibyo Gakkai Zasshi; 2021; 118(12):1122-1129. PubMed ID: 34897141
[TBL] [Abstract][Full Text] [Related]
28. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?
Alexander MP; Fervenza FC; De Vriese AS; Smith RJH; Nasr SH; Cornell LD; Herrera Hernandez LP; Zhang Y; Sethi S
J Nephrol; 2016 Apr; 29(2):203-209. PubMed ID: 26187133
[TBL] [Abstract][Full Text] [Related]
29. Infection-related Glomerulonephritis and C3 Glomerulonephritis - Similar Yet Dissimilar: A Case Report and Brief Review of Current Literature.
Chamarthi G; Clapp WL; Bejjanki H; Auerbach J; Koratala A
Cureus; 2020 Feb; 12(2):e7127. PubMed ID: 32140372
[TBL] [Abstract][Full Text] [Related]
30. Concomitant Granulomatosis with Polyangiitis and C3 Glomerulonephritis Causing Renal Failure.
Chaudhuri AA; Davis JT
Cureus; 2016 Feb; 8(2):e482. PubMed ID: 27004158
[TBL] [Abstract][Full Text] [Related]
31. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.
Ratanasrimetha P; Reddy VD; Kala J; Tchakarov A; Glass WF; Msaouel P; Lin JS
Front Immunol; 2022; 13():898811. PubMed ID: 35967405
[TBL] [Abstract][Full Text] [Related]
32. Interstitial nephritis with pembrolizumab: A case report and review.
Peláez Bejarano A; Montero Pérez O; Inoriza Rueda A; Garrido Martínez MT
J Oncol Pharm Pract; 2021 Jun; 27(4):1046-1051. PubMed ID: 33040674
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH
Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370
[TBL] [Abstract][Full Text] [Related]
34. C3 glomerulonephritis along with light chain proximal tubulopathy without crystal deposits in multiple myeloma: a case report.
Xu J; Yu X; Wang S; Yan M; Wang M; Ou J; Wang L; Liu H; Cen X
World J Surg Oncol; 2021 Jan; 19(1):24. PubMed ID: 33482806
[TBL] [Abstract][Full Text] [Related]
35. Mini review: A unique case of crescentic C3 glomerulonephritis.
Palamuthusingam D; Mantha M; Oliver K; Bavishi K; Dheda S
Nephrology (Carlton); 2017 Mar; 22(3):261-264. PubMed ID: 28205354
[TBL] [Abstract][Full Text] [Related]
36. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
37. C3 glomerulopathy: clinicopathologic features and predictors of outcome.
Medjeral-Thomas NR; O'Shaughnessy MM; O'Regan JA; Traynor C; Flanagan M; Wong L; Teoh CW; Awan A; Waldron M; Cairns T; O'Kelly P; Dorman AM; Pickering MC; Conlon PJ; Cook HT
Clin J Am Soc Nephrol; 2014 Jan; 9(1):46-53. PubMed ID: 24178974
[TBL] [Abstract][Full Text] [Related]
38. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
Alessi JV; Ricciuti B; Alden SL; Bertram AA; Lin JJ; Sakhi M; Nishino M; Vaz VR; Lindsay J; Turner MM; Pfaff K; Sharma B; Felt KD; Rodig SJ; Gainor JF; Awad MM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824161
[TBL] [Abstract][Full Text] [Related]
39. [Clinical and pathological analysis of IgA nephropathy with acute kidney injury].
Chen MG; Ye XH; Liang HY; Yang Q
Zhonghua Er Ke Za Zhi; 2016 Aug; 54(8):610-3. PubMed ID: 27510875
[TBL] [Abstract][Full Text] [Related]
40. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
